TLSI (TriSalus Life Sciences) Total Assets : $27.48 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences Total Assets?

TriSalus Life Sciences's Total Assets for the quarter that ended in Sep. 2024 was $27.48 Mil.

During the past 12 months, TriSalus Life Sciences's average Total Assets Growth Rate was 33.00% per year.

Total Assets is connected with ROA %. TriSalus Life Sciences's annualized ROA % for the quarter that ended in Sep. 2024 was -32.04%. Total Assets is also linked to Revenue through Asset Turnover. TriSalus Life Sciences's Asset Turnover for the quarter that ended in Sep. 2024 was 0.25.

TriSalus Life Sciences Total Assets Historical Data

The historical data trend for TriSalus Life Sciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TriSalus Life Sciences Total Assets Chart

TriSalus Life Sciences Annual Data

Trend

Dec21

Dec22

Dec23

Total Assets

37.84

22.00

25.73

TriSalus Life Sciences Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial						33.55	25.73	17.89	32.43	27.48

TriSalus Life Sciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

TriSalus Life Sciences's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-25.938	+	51.663
	=	25.73

TriSalus Life Sciences's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	-20.434	+	47.911
	=	27.48

TriSalus Life Sciences (NAS:TLSI) Total Assets Explanation

Total Assets is connected with ROA %.

TriSalus Life Sciences's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-9.596	/	( (32.431	+	27.477)	/ 2 )
	=	-9.596	/	29.954
	=	-32.04 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

TriSalus Life Sciences's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	7.349	/	( (32.431	+	27.477)	/ 2 )
=	7.349	/	29.954
=	0.25

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

TriSalus Life Sciences Total Assets Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

TriSalus Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

6272 W. 91st Avenue, Westminster, CO, USA, 80031

Website

https://www.trisaluslifesci.com

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines?Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Executives

Mats Wahlstrom	director, 10 percent owner	500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Mary T Szela	director, officer: CEO and President	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
George Kelly Martin	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jodi Devlin	officer: President, Therapeutics	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
James Alecxih	officer: President, Device Technology	C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Bryan F. Cox	officer: Chief Scientific & Manufact.	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks	director	C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
Jennifer Stevens	officer: Chief Regulatory Officer	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Richard Marshak	officer: Sr.VP, Corp. Dev. & Strategy	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Anil K. Singhal	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Sean Murphy	director, officer: Chief Financial Officer	C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz	officer: Chief Medical Officer	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Von Eschenbach Andrew C.	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Equity Ab Frankenius	10 percent owner	BOX 984, BORAS V7 SE-501 10